Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Hansa Biopharma – Presentation of Half-Year Report 2023

Af HC Andersen Capital
Hansa Biopharma

Meet and ask questions to Head of IR Klaus Sindahl from Hansa Biopharma Thursday the 20th of July at 11 AM CEST when he presents the Half-Year report and the latest development in the pipeline.

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA.

Disclaimer: HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 09.59AM on 21/06-2023.

Seneste videoer

Nordic Bloom - Live fra Silicon Valley: Mød Jared Heyman fra Rebel Fondene
10.03.2026, 15.00
Gubra – Presentation of Phase 1 Topline Results on ABBV-295 long-acting amylin analog
10.03.2026, 13.30 Gubra
Hanza, Capital Markets Day, CMD, 2026
10.03.2026, 13.00 HANZA
HCA Morgenbørs 09/03 - Et store fald på futures fronten, oliepriser har krydset 100 og øget nervøsitet omkring finansiering af AI udbygningen
10.03.2026, 09.26 Torm
HCA Morgenbørs 10/03 - Europæiske futures indikerer et re-bound
10.03.2026, 09.15 Rockwool
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.